AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALTERITY THERAPEUTICS LTD

0.445

-0.035-7.29%

Volume:257.65K

Turnover:118.54K

Market Cap:96.79M

PE:-4.00

High:0.480

Open:0.480

Low:0.445

Close:0.480

52wk High:0.785

52wk Low:0.350

Shares:217.51M

Float Shares:149.50M

Volume Ratio:2.23

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.111

EPS(LYR):-0.111

ROE:-54.98%

ROA:-34.08%

PB:2.27

PE(LYR):-4.00

Loading ...

Overview Company News Filings

Alterity Therapeutics - FDA Concurs With Ath434 50 Mg Twice Daily Dose for Phase 3

THOMSON REUTERS

Alterity Therapeutics - Phase 3 Trial Activities on Track to Initiate by Year-End 2026

THOMSON REUTERS

Alterity Therapeutics Ltd-Alterity and FDA Agree on Phase 3 Program for Ath434 in MSA-Ath

THOMSON REUTERS

Share Consolidation Effective, Trading Under ATHDA-ATH

Change of Registered Office Address-ATH

Hyperliquid (HYPE) Hits All-Time High After CFTC Landmark Approval of First-Ever Perpetual Futures

Alterity Therapeutics Says Data Presentations Support Phase Three Development for Multiple System Atrophy Treatment Candidate

MT Newswires Live

Alterity data support advancing ATH434 into Phase 3 MSA trial

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

MT Newswires Live

Alterity study shows QSM MRI tracks iron buildup, severity in multiple system atrophy

Alterity highlights ATH434 MSA trial results using CSF NfL covariate at MDSANZ meeting

Alterity Therapeutics director Ann Michelle Cunningham files initial beneficial ownership statement

Alterity Therapeutics announces upcoming shareholder meeting

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on Ath434 Phase 3 Program in Multiple System Atrophy

THOMSON REUTERS

Alterity says FDA backs ATH434 Phase 3 manufacturing plans for multiple system atrophy trial

BRIEF-Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program

Alterity Therapeutics - Alignment Reached With FDA on Cmc Elements for Ath434 Phase 3 Program

THOMSON REUTERS

Alterity Therapeutics Ltd - End-of-Phase 2 FDA Meeting Remains on Track for Mid-2026

THOMSON REUTERS

Alterity says Phase 2 ATH434 slows MSA decline on MuSyCA at week 52

USDT supply hits fresh $188b ATH as Tether tightens grip on stablecoins

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/ATH.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATH.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","market":"AU","secType":"STK","nameCN":"ALTERITY THERAPEUTICS LTD","latestPrice":0.445,"timestamp":1789095784079,"preClose":0.48,"halted":0,"volume":257646,"delay":0,"changeRate":-0.07291666666666662,"nameEN":"ALTERITY THERAPEUTICS LTD","floatShares":149498066,"shares":217508326,"eps":-0.1112,"marketStatus":"Trading","change":-0.035,"latestTime":"09-11 13:10:09 AEST","open":0.48,"high":0.48,"low":0.445,"amount":118537,"amplitude":0.072917,"askPrice":0.455,"askSize":5077,"bidPrice":0.45,"bidSize":11077,"shortable":3,"etf":0,"ttmEps":-0.1112,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789106400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.48,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":2.234795,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATH.AU","preClose":0.48,"auctionPrice":0.48,"auctionVolume":696,"auctionTime":1789084741231,"referenceTime":1789036203090,"auction":1,"marketStatus":"盘前竞价","timestamp":1789084741231}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATH.AU\",,,,,undefined,":{"symbol":"ATH.AU","floatShares":149498066,"roa":"-34.08%","roe":"-54.98%","lyrEps":-0.1112,"volumeRatio":2.234795,"shares":217508326,"dividePrice":0,"high":0.48,"amplitude":0.072917,"preClose":0.48,"low":0.445,"week52Low":0.35,"pbRate":"2.27","psRate":"26.81","week52High":0.785,"institutionHeld":0,"latestPrice":0.445,"committee":0.371425,"eps":-0.1112,"divideRate":0,"volume":257646,"delay":0,"ttmEps":-0.1112,"open":0.48,"prevYearClose":0.4,"prevWeekClose":0.5,"prevMonthClose":0.505,"prevQuarterClose":0.575,"fiveDayClose":0.5,"twentyDayClose":0.545,"sixtyDayClose":0.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATH.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-06-03","symbol":"ATH.AU","defaultRemindTime":1780444800000,"type":"split","dateTimestamp":1780408800000,"forFactor":50,"toFactor":1,"ratio":50}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATH.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATH.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642464491","title":"Alterity Therapeutics - FDA Concurs With Ath434 50 Mg Twice Daily Dose for Phase 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2642464491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642464491?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:05","pubTimestamp":1781003100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA2CHXHM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642346449","title":"Alterity Therapeutics - Phase 3 Trial Activities on Track to Initiate by Year-End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642346449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642346449?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:05","pubTimestamp":1781003100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nTUA2CHXHM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642944437","title":"Alterity Therapeutics Ltd-Alterity and FDA Agree on Phase 3 Program for Ath434 in MSA-Ath","url":"https://stock-news.laohu8.com/highlight/detail?id=2642944437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642944437?lang=en_us&edition=fundamental","pubTime":"2026-06-09 07:01","pubTimestamp":1780959679,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUE5HMYMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640786180","title":"Share Consolidation Effective, Trading Under ATHDA-ATH","url":"https://stock-news.laohu8.com/highlight/detail?id=2640786180","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640786180?lang=en_us&edition=fundamental","pubTime":"2026-06-04 07:49","pubTimestamp":1780530561,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260603:nASXc5qjHF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nASX3jDwYg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640297116","title":"Change of Registered Office Address-ATH","url":"https://stock-news.laohu8.com/highlight/detail?id=2640297116","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640297116?lang=en_us&edition=fundamental","pubTime":"2026-06-03 14:59","pubTimestamp":1780469947,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260603:nASX6GvllX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nASX90HBYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639609389","title":"Hyperliquid (HYPE) Hits All-Time High After CFTC Landmark Approval of First-Ever Perpetual Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2639609389","media":"utoday","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639609389?lang=en_us&edition=fundamental","pubTime":"2026-05-29 16:38","pubTimestamp":1780043880,"startTime":"0","endTime":"0","summary":"The decision by the Commodity Futures Trading Commission (CFTC), which opened the way for Kalshi to launch the first regulated perpetual futures in the United States, caused turbulence across the cryp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/hyperliquid-hype-hits-all-time-high-after-cftc-landmark-approval-of-first-ever-perpetual-futures","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/hyperliquid-hype-hits-all-time-high-after-cftc-landmark-approval-of-first-ever-perpetual-futures","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BK7067","LARK","ATH.AU","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636881349","title":"Alterity Therapeutics Says Data Presentations Support Phase Three Development for Multiple System Atrophy Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2636881349","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636881349?lang=en_us&edition=fundamental","pubTime":"2026-05-19 11:45","pubTimestamp":1779162331,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  said data it presented at three medical conferences support the advancement of its ATH434 treatment candidate for multiple system atrophy into phase three clinical development, according to a Tuesday filing with the Australian bourse.One presentation highlighted new research that shows Alterity's magnetic resonance imaging approach can detect the neurodegenerative disease, which is characterized by failure of the autonomic nervous system and impaired movement, in its earliest stages.Meanwhile, a new analysis of the company's phase two trial showed evidence that supports ATH434's impact on slowing the progression of multiple system atrophy.\"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for [multiple system atrophy], a rare and devastating disease with no approved therapy,\" said Alterity Therapeutics CEO David Stamler.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK7067","ATH.AU","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636888118","title":"Alterity data support advancing ATH434 into Phase 3 MSA trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636888118","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636888118?lang=en_us&edition=fundamental","pubTime":"2026-05-19 08:59","pubTimestamp":1779152341,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics highlighted new conference presentations that it says support advancing ATH434 into a Phase 3 trial in multiple system atrophy, with results already presented at three medical meetings.The update points to Phase 2 findings that indicated a statistically significant slowing of disease progression, positioning the program as a potential disease-modifying approach in a condition with no approved therapy.Separate imaging research presented at an MRI conference described an approach that could help identify patients earlier and track disease-related brain changes over time, which Alterity is using to shape Phase 3 trial design.An end-of-Phase 2 meeting with the FDA is targeted for mid-2026 to confirm the Phase 3 path forward.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL8wtqLf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634478966","title":"Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634478966","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634478966?lang=en_us&edition=fundamental","pubTime":"2026-05-11 09:42","pubTimestamp":1778463728,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics  said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy , according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided \"objective evidence of target engagement.\"The peer-reviewed publication validates the company's approach and \"reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA,\" Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0053671581.USD","ATH.AU","BK4139","LU0757428866.USD","LU2125909916.SGD","LU2211815571.USD","LU0154245673.USD","LU0728928796.USD","LU0154245756.USD","LU1923622291.USD","BK4143","LU2125909759.SGD","BK7067","LU1815336091.USD","BK4007","LENZ","BK4539","MSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634229144","title":"Alterity study shows QSM MRI tracks iron buildup, severity in multiple system atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2634229144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634229144?lang=en_us&edition=fundamental","pubTime":"2026-05-11 07:59","pubTimestamp":1778457543,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics highlighted a newly published, peer-reviewed NeuroImage study supporting quantitative susceptibility mapping MRI as an imaging biomarker for Multiple System Atrophy, with results already presented in the publication.The analysis from the bioMUSE natural history study indicates the imaging method can detect disease-specific brain iron accumulation, help distinguish MSA from Parkinson’s disease, and track clinical severity, including in early-stage disease.Alterity said it previously used the approach in its Phase 2 trial of lead candidate ATH434, citing improved diagnostic accuracy and objective evidence of target engagement.Company positioned the findings as supportive of earlier diagnosis strategies and as a tool to evaluate iron-modulating therapies in MSA, including ATH434.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nNDL2v9Tp1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633571167","title":"Alterity highlights ATH434 MSA trial results using CSF NfL covariate at MDSANZ meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2633571167","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633571167?lang=en_us&edition=fundamental","pubTime":"2026-05-07 09:55","pubTimestamp":1778118924,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics scheduled new clinical updates on its lead drug candidate ATH434 in Multiple System Atrophy at medical meetings in May 2026, with results to be presented in the future.Conference disclosures include an analysis from a randomized, double-blind, placebo-controlled study of ATH434 that frames outcomes using a cerebrospinal fluid biomarker as a covariate, positioning the dataset for clinical interpretation rather than reporting a new trial start.Management will also present an ATH434 clinical update with Phase 3 planning at an MSA-focused symposium in London on May 18, 2026, signaling progression toward late-stage development decisions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. publishe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLSW5cJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575126","title":"Alterity Therapeutics director Ann Michelle Cunningham files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575126","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631575126?lang=en_us&edition=fundamental","pubTime":"2026-04-30 08:05","pubTimestamp":1777507545,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics filed an initial Form 3 disclosing Ann Michelle Cunningham as a director, with the filing triggered on April 17, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL1G4nSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631607519","title":"Alterity Therapeutics announces upcoming shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631607519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631607519?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:13","pubTimestamp":1777464807,"startTime":"0","endTime":"0","summary":"Shareholders will vote on election of directors Julian Babarczy, Ann Cunningham.Meeting agenda includes a 1-for-50 consolidation of issued share capital, with options consolidated on same basis.Proposals also cover issuing up to 100,000,000 options to Babarczy, up to 50,000,000 options to Montoya Pty Ltd ATF Buttercup Trust.Items include amending constitution to set an issue cap, with approval sought to issue up to 1,087,541,633 securities under an incentive plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Apri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL6TZR1q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393237","title":"Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on Ath434 Phase 3 Program in Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393237","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393237?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:24","pubTimestamp":1777289099,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA23XWPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATH.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630367526","title":"Alterity says FDA backs ATH434 Phase 3 manufacturing plans for multiple system atrophy trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630367526","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630367526?lang=en_us&edition=fundamental","pubTime":"2026-04-27 18:22","pubTimestamp":1777285371,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics reported positive FDA feedback from a second Type C meeting on its planned Phase 3 program for ATH434 in multiple system atrophy.Regulators backed Alterity’s chemistry, manufacturing, and control plans, supporting readiness to start Phase 3 while manufacturing scale-up continues.No clinical results were presented in this update.Alterity kept its End-of-Phase 2 meeting timeline unchanged, targeting mid-2026 to finalize Phase 3 plans with FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDLbvjxbR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630416330","title":"BRIEF-Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2630416330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630416330?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:20","pubTimestamp":1777252831,"startTime":"0","endTime":"0","summary":"BRIEF-Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 ProgramApril 27  - Alterity Therapeutics Ltd ATH.AX:RECEIVES POSITIVE FDA FEEDBACK ON ATH434 PHASE 3 PROGRAM IN MULTIPLE SYSTEM ATROPHYEND-OF-PHASE 2 FDA MEETING REMAINS ON TRACK FOR MID-2026Further company coverage: ATH.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN418032:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630362334","title":"Alterity Therapeutics - Alignment Reached With FDA on Cmc Elements for Ath434 Phase 3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2630362334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630362334?lang=en_us&edition=fundamental","pubTime":"2026-04-27 06:56","pubTimestamp":1777244198,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nFWN418032:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630334360","title":"Alterity Therapeutics Ltd - End-of-Phase 2 FDA Meeting Remains on Track for Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630334360","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630334360?lang=en_us&edition=fundamental","pubTime":"2026-04-27 06:56","pubTimestamp":1777244198,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nFWN418032:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629012130","title":"Alterity says Phase 2 ATH434 slows MSA decline on MuSyCA at week 52","url":"https://stock-news.laohu8.com/highlight/detail?id=2629012130","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629012130?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:17","pubTimestamp":1776853035,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics presented new analyses from its Phase 2 ATH434-201 trial in multiple system atrophy during a Late Breaking Science session at American Academy of Neurology annual meeting.Analyses indicated ATH434 slowed functional decline versus placebo on a newly developed composite scale designed to better track disease progression.Results also supported previously reported benefits across daily function and neurological assessment, reinforcing ATH434’s disease-modifying profile.Update positions Alterity to move toward Phase 3 discussions with regulators.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL9wPRkk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","ATH.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629056137","title":"USDT supply hits fresh $188b ATH as Tether tightens grip on stablecoins","url":"https://stock-news.laohu8.com/highlight/detail?id=2629056137","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629056137?lang=en_us&edition=fundamental","pubTime":"2026-04-22 00:14","pubTimestamp":1776788087,"startTime":"0","endTime":"0","summary":"Tether CEO Paolo Ardoino says USDT supply has hit a record $188b, cementing the stablecoin’s dominance as broader stablecoin liquidity sits near all-time highs.Tether CEO Paolo Ardoino says USDT supply has reached a record $188 billion.The new peak comes weeks after stablecoins hit a combined $315 billion market cap.USDT now dominates the sector as its float marches higher despite recent outflows.Tether CEO Paolo Ardoino says the circulating supply of USDT has reached a new all-time high of $188 billion, extending the stablecoin’s lead over rivals as on-chain dollar demand climbs.In a post on X,  Ardoino highlighted the new record as another milestone for what he has called a “digital dollar designed for the masses,” after previously disclosing that more than 550 million people in emerging markets now rely on USDT for payments and savings.For more context on the stablecoin landscape, crypto.news recently reported on the stablecoin market’s $226.8 billion all-time high in early 2025 and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/usdt-supply-hits-fresh-188b-ath-as-tether-tightens-grip-on-stablecoins/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/usdt-supply-hits-fresh-188b-ath-as-tether-tightens-grip-on-stablecoins/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["BK7067","CRCL","CRCO","BK4162","LU2360107671.USD","LU1861558580.USD","ATH.AU","ATH","CCUP","LU1668664300.SGD","LU0106831901.USD","LU1861220207.SGD","BK4023","CRCA","CRCD","ICRC","LU1861217088.USD","CRCG","LU1791807156.HKD","USDT.USD.CC","USDT.USD.HKCC","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":56,"code":"91000000","status":"200"}]}}